Pretreatment with MM-121 followed by NRG-1 stimulation rendered ligand-induced ErbB3 activation ineffective and combination of MM-121 with erlotinib completely abolished AKT activation in pancreatic cancer cells (Figure 9A). This evidence concerns the gene ERBB3 and familial pancreatic carcinoma.